Vancouver, British Columbia--(Newsfile Corp. - June 28, 2017) - THC BioMed (CSE: THC) (OTCQB: THCBF) (FSE: TFHD) has received
its first order to export dried marijuana to Germany. The company, an authorized licensed producer of dried Marijuana for Medical
Purposes with a production only license for fresh marijuana and cannabis oil, is moving forward to meet the regulatory requirements
to export to the European Union.
InvestmentPitch.com has produced a "video"
which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "THC BioMed" in the search box. The video is also available
on YouTube.
Although Germany, with a population of more than 80 million, twice the size of California, has legalized medical cannabis, there
is no current domestic production. Under new German laws, people suffering from serious illnesses such as multiple sclerosis, or
even chronic pain, lack of appetite and nausea are able to access medical cannabis. Germany exhibits the potential to be a massive
market.
THC currently offers 29 different genetic strains for sale and has the largest variety of genetic strains available in Canada
for home growers.
John Miller, President & CEO, stated: "THC intends to soon begin selling dried marihuana as an interim supply to registered
home growers at $4.20 per gram. We believe this would be the lowest price ever offered to medical patients in Canada. We are
pleased to offer this wholesale-type pricing to our fellow growers. The home growing market is expected to expand rapidly in the
event recreational marihuana is introduced."
The company recently closed the acquisition of Clone Shipper at a cost of US$1 million. The company is using the newly designed
Clone Shipper 3.0 containers to ship live cannabis plants across Canada and believes it is the one of the first companies in Canada
to ship live cannabis plants. The patented design allows for a LED light to keep the clone in the growing vegetative stage for 12
to 24 hours during shipment.
THC BioMed currently ships the most live Cannabis plants in Canada, and has the widest selection of strains available. It has
developed strains with a distinct herbal odor, resulting in a product which exhibits a less pungent marijuana smell when
smoked.
Dr. Ashish Dave, who previously consulted to the company, has joined the Board of Directors. Dr. Dave has a PHD in plant tissue
culture and a Master's Degree in botany.
The shares are trading at $0.43 and with 103 million shares currently outstanding, the company is capitalized at $44.3
million.
For more information, please visit www.THCbiomed.com, contact John Miller, President &
CEO, at 250-870-2512 or email info@THCbiomed.com.
About InvestmentPitch Media
Investmentpitch Media leverages the power of video, which together with its extensive distribution, positions a company's story
ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing
short videos based on significant news releases, research reports and other content of interest to investors.
CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com
